MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

36.63 -0.38

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

36.63

Max

37.02

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	11.426 89.037
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	14M 73M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+18.82% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	399M 2.1B
Ankstesnė atidarymo kaina	37.01
Ankstesnė uždarymo kaina	36.63

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-23 18:41; UTC

Uždarbis

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

2026-01-24 09:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-24 09:20; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-01-24 09:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-24 09:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-01-24 06:18; UTC

Įsigijimai, susijungimai, perėmimai

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

2026-01-23 22:30; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-23 22:30; UTC

Rinkos pokalbiai

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

2026-01-23 22:03; UTC

Uždarbis

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

2026-01-23 21:52; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

2026-01-23 21:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-01-23 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-23 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-23 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-01-23 21:39; UTC

Uždarbis

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

2026-01-23 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

2026-01-23 21:12; UTC

Uždarbis

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

2026-01-23 20:31; UTC

Uždarbis

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

2026-01-23 20:12; UTC

Rinkos pokalbiai

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

2026-01-23 20:07; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

2026-01-23 19:36; UTC

Rinkos pokalbiai

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

2026-01-23 19:30; UTC

Rinkos pokalbiai

Uždarbis

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

2026-01-23 19:18; UTC

Rinkos pokalbiai

Gold and Silver Step Up to More Records -- Market Talk

2026-01-23 19:15; UTC

Uždarbis

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

2026-01-23 18:53; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

2026-01-23 18:21; UTC

Uždarbis

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

2026-01-23 18:19; UTC

Rinkos pokalbiai

Intel Seen as Increasingly Confident on Demand -- Market Talk

2026-01-23 17:59; UTC

Uždarbis

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

2026-01-23 17:57; UTC

Rinkos pokalbiai

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

2026-01-23 17:57; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

18.82% į viršų

12 mėnesių prognozė

Vidutinis 43.75 USD 18.82%

Aukščiausias 55 USD

Žemiausias 32 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.